Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis - Report - MDSpire

Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis

  • By

  • Rui He

  • Limin Huang

  • Yang Chen

  • Minqi Liu

  • Miaomiao Xie

  • Honglei Yuan

  • Ling Mao

  • January 3, 2026

  • 0 min

Share

Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis

Overview

This study evaluates the potential of serum KL-6 levels and immune-inflammatory markers in diagnosing complicated silicosis. Findings suggest that KL-6 may serve as a valuable biomarker for early detection and risk stratification in patients with silicosis.

Background

Silicosis is a significant occupational lung disease caused by silica exposure, leading to irreversible lung damage and high morbidity rates. Current diagnostic methods have limitations, often detecting disease only after substantial structural damage has occurred. There is an urgent need for reliable serum biomarkers to facilitate early diagnosis and improve patient management.

Data Highlights

No numerical data available in the provided source.

Key Findings

  • Serum KL-6 levels were significantly elevated in patients with complicated silicosis compared to dust-exposed workers.
  • KL-6 levels correlated with disease severity and progression in silicosis patients.
  • Combining KL-6 with inflammatory markers improved diagnostic accuracy for complicated silicosis.
  • Current diagnostic methods for silicosis often fail to detect early disease stages, highlighting the need for biomarkers.
  • KL-6 has been recognized as a leading candidate biomarker for interstitial lung diseases.

Clinical Implications

Clinicians should consider measuring serum KL-6 levels in patients with occupational silica exposure to enhance early diagnosis of complicated silicosis. The integration of KL-6 with existing inflammatory markers may improve risk stratification and patient management.

Conclusion

Serum KL-6 shows promise as a non-invasive biomarker for early detection of complicated silicosis, potentially transforming clinical approaches to this occupational disease.

References

  1. Clinical Rheumatology, 2023 -- Clinical Features of Systemic Sclerosis in Patients with Occupational Silicosis
  2. Pediatric Cardiology, 2025 -- Distinguishing Kawasaki Disease from Multisystem Inflammatory Syndrome in Pediatric Patients Through Blood Composite Scores: Implications for Clinical Outcomes and Predictive Measures
  3. Clinical Rheumatology, 2023 -- Forecasting the Advancement of Pulmonary Fibrosis in Patients with Interstitial Lung Disease Linked to Anti-Synthetase Syndrome
  4. Archives of Toxicology, 2023 -- Gasdermin D-formed membrane pores regulate the release of IL-1α from necrotic macrophages following exposure to silica rich in NFS
  5. Silicosis Reporting Guidelines | Surveillance | CDC
  6. Scientific Reports, 2025 -- Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
  7. Silicosis Reporting Guidelines | Surveillance | CDC
  8. Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease | Scientific Reports

Original Source(s)

Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis

  • by Rui He, Limin Huang, Yang Chen, Minqi Liu, Miaomiao Xie, Honglei Yuan, Ling Mao

  • January 3, 2026

Related Content

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.

Pulmonary surveillance in inborn errors of immunity: current challenges and emerging approaches

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.